Meta-Analysis of the Relation of Body Mass Index to Cardiovascular Outcomes in Patients Receiving Intensive Low-Density Lipoprotein Cholesterol Lowering Therapy

The impact of body mass index (BMI) on cardiovascular outcomes among patients receiving intensive low-density lipoprotein cholesterol (LDL-C) lowering therapy is uncertain. We performed meta-analysis of 29 randomized controlled trials using PubMed, Embase and CENTRAL through April 2019. Therapies were grouped as more intensive LDL-C lowering therapy (statins, ezetimibe  + statin or PCSK9 inhibitors) and less intensive LDL-C lowering therapy (less potent active control or placebo). Random effects meta-regressions and meta-analyses were performed to evaluate association of BMI with cardiovascular endpoints.

Source: The American Journal of Cardiology - December 8, 2019 Category: Cardiology Authors: Safi U. Khan, Muhammad U. Khan, Haris Riaz, Paolo Raggi, Shahul Valavoor, Muhammad Zia Khan, Michalina Ko łodziejczak, Muhammad Shahzeb Khan, Troy Krupica, Mohamed Alkhouli, Eliano P. Navarese Source Type: research